EcoDrugPlus

Neuropeptide Y Receptor Y4-2

Ensembl ID : ENSTGUG00000007925
Gene Symbol: NPY4R2
3 Cross references
116 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neuropeptide Y Receptor Y5

Ensembl ID : ENSTGUG00000018793
Gene Symbol: NPY5R
3 Cross references
135 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neurotensin Receptor 1

Ensembl ID : ENSTGUG00000029344
Gene Symbol: NTSR1
3 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neurotrophic Receptor Tyrosine Kinase 1

Ensembl ID : ENSTGUG00000021241
Gene Symbol: NTRK1
1 Cross references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSTGUG00000003077
Gene Symbol: NTRK2
3 Cross references
285 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSTGUG00000008364
Gene Symbol: NTRK3
3 Cross references
269 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nicastrin

Ensembl ID : ENSTGUG00000004337
Gene Symbol: NCSTN
1 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSTGUG00000003039
Gene Symbol: NAMPT
3 Cross references
235 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nitric Oxide Synthase 2

Ensembl ID : ENSTGUG00000008604
Gene Symbol: NOS2
1 Cross references
165 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Notch Receptor 1

Ensembl ID : ENSTGUG00000006073
Gene Symbol: NOTCH1
3 Cross references
268 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSTGUG00000003595
Gene Symbol: NFKB1
3 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSTGUG00000007491
Gene Symbol: NFKB2
3 Cross references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).